YM BioSciences provides update on tesmilifene pivotal trial MISSISSAUGA, ON, Jan. 15 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), an...
YM Biosciences partners with TTY Biopharm to develop Tesmilifene in Taiwan - YM and TTY will Initially Study Tesmilifene in Patients with Hepatic...
YM Biosciences reports first quarter 2007 operational and financial results MISSISSAUGA, ON, Nov. 10 /CNW/ - YM BioSciences Inc. (AMEX:YMI...
YM BioSciences announces results of AeroLEF(TM) Phase IIb open-label study - Data presented at ASA Annual Meeting show inhaled AeroLEF(TM...
YM BioSciences Announces AeroLEF(TM) Phase IIb Interim Review - Benefit observed compared with placebo; Clinical trial to continue as planned...
YM BioScience receives clearance to import nimotuzumab for clinical research in the US - Clearance will allow YM to submit an Investigational New...
YM Biosciences reports 2006 year end operational and financial results MISSISSAUGA, ON, Sept. 22 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM...
YM BioSciences announces independent Data Safety Monitoring Board recommends tesmilifene pivotal trial continue as planned MISSISSAUGA, ON, Aug...
YM Biosciences Licenses Monoclonal Antibody, Nimotuzumab, to Daiichi Pharmaceutical for Japan MISSISSAUGA, ON, July 31 /CNW/ - YM BioSciences Inc...
YM BioSciences reports anti-EGFr drug nimotuzumab approved in India for treatment of head and neck cancer MISSISSAUGA, ON, July 20 /CNW/ - YM...
Attention Business/Health Editors: YM Biosciences announces independent Data Safety Monitoring Board recommends tesmilifene pivotal trial continue...
YM BioSciences announces update on tesmilifene pivotal trial MISSISSAUGA, ON, June 7 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), a...
YM BioSciences starts patient treatment in Phase II trial combining tesmilifene with Taxotere(R) - Study to enroll up to 39 women with rapidly...
YM BioSciences reports third quarter 2006 operational and financial results MISSISSAUGA, ON, May 12 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM...
YM BioSciences completes acquisition of Eximias - U.S. based Eximias provides YM with seasoned oncology management team and US $29 million...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.